Jefferies & Co. is out with a research report on ZOLL Medical Corp. ZOLL and it is reiterating its Buy rating and $70 price target.
In a note to clients, Jefferies & Co. writes, "ZOLL's 10Q disclosed the issuance of a draft coverage revision which would limit Medicare reimbursement for LifeVest; the proposed revision would prohibit use of LifeVest during ICD waiting periods. As it is used primarily during waiting periods to protect at-risk patients, a reconsideration of this reimbursement is troubling but also not well supported by current clinical practice. A change in reimbursement policy appears unlikely."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in